Optomed Plc is a party to a shareholders’ agreement concerning the company dated 14 August 2015 between Aura Capital Oy, Finnish Industry Investment Ltd, Cliff Swallow Investment Ltd, Mankato Capital Ltd, Uppland Kapital AB, Halma Ventures Limited, Alnair Investments, Robert Bosch Venture Capital GmbH, Shanghai Cenova Innovation Venture Fund (Limited Partnership), Cenova China Healthcare Fund IV, Seppo Kopsala, Markku Virta, David Oak and Optomed Oy.
According to the shareholders’ agreement, Halma Ventures Limited have had the right to nominate two members to the Board of Directors and Aura Capital Oy, Alnair Investments, Finnish Industry Investment Ltd and Robert Bosch Venture Capital GmbH each have had the right to nominate one member. Other shareholders have had the right to jointly nominate two members to the Board of Directors. Halma Ventures Limited has appointed Matthew Hallam and Jens Umehag, Aura Capital Oy has appointed Petri Salonen, Alnair Investments has appointed Jun Wu and Robert Bosch Venture Capital GmbH has appointed Ingo Ramesohl to the Board of Directors of the Company.
According to the terms of the above mentioned shareholders’ agreement, the agreement will cease to be in effect as of the listing.
Optomed is not aware of any other shareholder agreements between the shareholders of the company that would be in effect.